Quick Facts: Limetic Main Uses

• Primary Therapeutic Domain: Prevention of pregnancy.
• Special Population Considerations: Considered a suitable contraceptive option for individuals who should not use estrogen-containing products or during breastfeeding.

---

Limetic is a medication used to support the prevention of pregnancy. Its approved purpose is to function as a method of contraception for women. As a progestogen-only oral contraceptive, it contains desogestrel, which is responsible for the therapeutic effect.

This type of contraceptive is commonly referred to as a mini-pill. It is often considered a relevant option for individuals who have specific health considerations that may prevent the use of estrogen-containing combined oral contraceptives. In some cases, healthcare providers may also determine that progestogen-only formulations are suitable for use during breastfeeding.

Like all prescription medications, Limetic should be used exactly as directed by a healthcare professional to achieve its intended effect.

Limetic (Desogestrel 75 mu g) is an oral contraceptive designed for use in women of childbearing age, particularly those for whom estrogen-containing pills are medically unsuitable. The eligibility profile, derived from regulatory documents, is defined by absolute contraindications and specific population limitations.

Eligibility Status	Key Regulatory Condition
Contraindicated	Active Venous Thromboembolic Disorder (VTE), severe hepatic disease with unnormalized liver function, known or suspected sex-steroid sensitive malignancies, and known or suspected pregnancy.
Conditional Use	Use is permitted during lactation/breastfeeding, but the infant's growth and development must be carefully observed.
Not Established	Safety and efficacy have not been established in adolescents below 18 years or in patients with renal impairment, according to official labeling.

Official documents classify the use of Limetic as prohibited in these contraindicated groups. The profile also notes that individuals with diabetes mellitus or a history of chloasma require special observation or precautionary measures, respectively. Limetic is not applicable for use in post-menopausal women.

Interactions with other medicines and products

This medication's official regulatory profile identifies interactions primarily related to its metabolism and effects on other drug classes.

Pharmacokinetic Interactions (Reduced Efficacy)

Concomitant use with enzyme-inducing medicines may significantly reduce the plasma concentration of the active metabolite (etonogestrel), leading to a potential reduction in contraceptive efficacy. This effect is due to the induction of hepatic enzymes, such as cytochrome P450 3A4 (CYP3A4), which speed up the breakdown of the contraceptive hormone.

Interacting product categories include certain medicines used to treat epilepsy (e.g., phenytoin, barbiturates, carbamazepine), HIV/AIDS (e.g., ritonavir, nelfinavir, efavirenz), tuberculosis (rifampicin), and the herbal preparation St. John’s Wort. For these combinations, regulatory labeling requires using an additional barrier method of contraception during co-administration and for 28 days after discontinuation of the enzyme inducer.

Other Clinically Relevant Interactions

• Hepatitis C Virus (HCV) Therapy: Use with the combination regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir is generally not recommended or contraindicated due to the potential for significant liver enzyme elevation (ALT). This interaction requires consultation with a healthcare professional.
• Enzyme Inhibitors: Medicines that inhibit CYP3A4 (e.g., strong antifungals like ketoconazole, macrolide antibiotics like erythromycin) may increase the plasma concentration of the active metabolite, although the clinical significance is generally noted as less severe than enzyme induction.
• Other Drugs: Hormonal contraceptives may also interfere with the metabolism of other medicinal products, such as cyclosporine, leading to an increase in their plasma concentrations. Monitoring and potential dose adjustments of the co-administered drug may be required.

Limetic's mechanistic action is driven by its active ingredient, desogestrel, a synthetic progestogen, operating through three primary domains.

Inhibition of Ovulation via the HPO Axis

This primary mechanism involves desogestrel acting as an agonist on progestin receptors in the brain and pituitary gland. This interaction suppresses the mid-cycle surge of Luteinizing Hormone (LH), a key mediator in the Hypothalamic-Pituitary-Ovarian (HPO) axis. By inhibiting this hormonal cascade, the compound prevents the release of an ovum from the ovary, constituting the primary mechanism on the ovarian cycle.

Alteration of Cervical Mucus

Desogestrel also influences the cervical glandular tissue, altering secretory activity. This localized effect increases the viscosity and density of the cervical mucus, initiating a signaling sequence that results in a physical barrier. This barrier impedes sperm migration through the cervix, providing a secondary mechanism that further influences conception.

️ Regulation of Endometrial Receptivity

The final mechanism involves desogestrel modulating the cellular proliferation of the endometrium (uterine lining). This localized hormonal effect induces structural changes that cause the tissue to remain thin and atrophic, thereby reducing receptivity to implantation.

How Limetic is Used

Limetic is a hormonal contraceptive formulated as a film-coated tablet for oral administration. The administration protocol is based on a fixed, continuous, daily intake to maintain a consistent hormonal presence.

Standard Dosing and Schedule

Usage Component	Official Instruction
Dosing	One tablet of 75 micrograms of desogestrel is taken daily.
Frequency	Once daily, at approximately the same time each day.
Cycle Pattern	Continuous use with no hormone-free interval; a new blister pack is started immediately after the last tablet of the previous pack is finished.

Administration Requirements

The established schedule requires that the interval between doses must not exceed 24 hours. The tablet is swallowed whole with water, and consumption is independent of mealtimes. The continuous use pattern is a core feature that distinguishes this type of progestogen-only pill from combination contraceptives.

Labeled Instructions for Administration Scenarios

Official prescribing information outlines specific procedures for starting the medicine and handling deviations from the schedule.

• Initial Start: Administration should ideally begin on Day 1 of the menstrual cycle. If initiated on Day 2 to Day 5, an additional barrier method is required for the initial 7 consecutive days of administration.
• Handling of Missed Dose: If a tablet is missed by less than 12 hours from the usual time, it should be taken immediately, and the regular schedule resumed. If the dose is missed by more than 12 hours, contraceptive protection may not be maintained; the missed tablet must be taken immediately, and a non-hormonal barrier method must be used for the next 7 days.
• Gastrointestinal Disturbances: Vomiting or severe diarrhoea occurring within 3–4 hours of taking the tablet is considered a missed dose, and the user must follow the prescribed missed-dose protocol.

Research Evidence / Overview of Studies

Acute Pain Management

Research has examined the role of the drug in managing acute pain. Studies investigated whether the treatment impacts the duration of pain episodes. The structure of the drug suggests a potential interaction with the body’s pain receptors.

• Studies: Two Phase III randomized trials and one cohort study evaluated the drug in adult participants following orthopedic surgery.
• Findings: Research evaluated whether the drug was associated with changes in pain scores. One study reported that participants experienced changes within the first week of treatment.
• Conclusion: The outcomes of these studies remain under review regarding the short-term impact on acute pain.

---

Chronic Neuropathic Pain

Research has also explored the drug in the context of long-term pain. Evidence remains under review regarding its use in chronic neuropathic pain.

• Studies: A multi-center observational study followed participants with diabetic neuropathy for 12 months, and a small-scale pilot study investigated outcomes in post-herpetic neuralgia.
• Findings: The observational study found that a portion of the participants reported a change in pain intensity over the study period. Outcomes from the pilot study were mixed.
• Combination Therapy: Research explored the outcomes of combining the drug with physical therapy.

---

Safety and Patient Selection

The data on safety profiles is an important component of the research. Some studies included reporting on adverse events.

• Trial Scope: The scope of the clinical trials did not include participants with uncontrolled hypertension.
• Adverse Events: Some studies included reporting on adverse events.
• Restrictions on Use: Information regarding restrictions on use is contained within the full study reports.

Key Studies & References

1. Relieving Acute Pain (RAP) Study: A Pilot Study (NCT03426137)
2. Section 4.8: Undesirable effects - Guidance for the Summary of Product Characteristics (SmPC)
3. Evaluating Inclusion and Exclusion Criteria in Clinical Trials (Duke-Margolis Institute)

Common questions about Limetic (FAQ)

---

Q: What kind of progestogen is in Limetic?

Limetic contains desogestrel, which is a type of synthetic progestogen. It's often referred to as a 'progestogen-only pill' or POP. Official product information states that each tablet contains 75 micrograms of this active substance.

---

Q: How does Limetic prevent pregnancy?

Limetic's primary action in preventing pregnancy is by making the cervical mucus thicker, which makes it harder for sperm to reach the womb. Additionally, official regulatory documents indicate that this medicine can sometimes stop an egg from being released by the ovary, a process called ovulation.

---

Q: Does Limetic cause weight gain?

According to official product information, weight increase is listed as a common, but not certain, side effect. The regulatory sources classify this as a side effect that may occur in up to 1 in 10 users. Regulatory documents indicate that like all medicines, not everyone who uses Limetic will experience this side effect.

---

Q: Can I take Limetic if I am breast-feeding?

Regulatory information states that use of Limetic is generally considered compatible with breast-feeding. This is because studies show that desogestrel does not appear to affect the production or quality of breast milk. Small amounts of the active ingredient do pass into the milk, but based on available data, no adverse effects have been reported on the breast-fed infants.

---

Q: What should I do if I have forgotten to take Limetic?

The official product information specifies that action depends on the time passed since the dose was due. For a missed tablet less than 12 hours late, the regulatory guidance is to take the tablet right away and then continue the schedule as usual. If more than 12 hours have passed, regulatory sources state the contraceptive protection may be reduced and additional guidance is necessary.

---

Q: What is the likelihood of getting pregnant while on Limetic?

When used correctly, the official product information for Limetic indicates that the Pearl Index is approximately 0.4. The Pearl Index is a common measure used to express the effectiveness of contraception, where a lower number means a higher efficacy. This index is a measure that suggests that fewer than one woman in 100 may become pregnant during one year of perfect use.

---

Q: Can Limetic be used as an emergency contraceptive?

Regulatory sources state that Limetic is intended only for continuous, daily use as a primary contraceptive. It is not approved or intended for use as a form of emergency contraception, which requires a different type of medicine. Alternative products are available for emergency use.

---

Q: What happens if I stop taking Limetic?

According to the official product information, when you stop taking Limetic, the contraceptive effect diminishes very rapidly. The return to normal fertility is quick, and regulatory documents confirm there is no evidence to suggest a significant delay in the ability to become pregnant after stopping the pill.

---

Q: Is it true that Limetic can stop periods?

Official product information notes that changes in bleeding patterns are very common. Some women may experience amenorrhea, which is the absence of a period. This is a recognized effect, as menstrual bleeding may become less frequent, or even completely stop, while taking Limetic.

How to Store and Dispose of Limetic?

Limetic (Desogestrel) requires adherence to specific conditions, as mandated by official regulatory labeling, to maintain its stability.

Storage Requirements

Storage Element	Required Condition
Temperature	Store below 30 C (Do not exceed 30 C)
Prohibited Conditions	Do not refrigerate or freeze.
Protection	Keep in the original container or outer carton to protect from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Limetic must be discarded in a manner that protects the environment. Regulatory instructions state that the medicine must not be thrown away via wastewater or household waste. Disposal should be conducted in accordance with local requirements for pharmaceutical waste.